A
Arecor Therapeutics PLC
LSE:AREC
Arecor Therapeutics PLC
LSE:AREC
Price:
68.5
GBX
3.01%
Market Closed
Market Cap:
£25.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
A
|
Arecor Therapeutics PLC
LSE:AREC
|
UK |
|
H
|
Hargreaves Lansdown PLC
LSE:HL
|
UK |
|
S
|
SC Estate Builder Bhd
KLSE:SCBUILD
|
MY |
|
Lee Chi Enterprises Co Ltd
TWSE:1517
|
TW |
|
Mountain Alliance AG
XETRA:ECF
|
DE |
|
B
|
Beenos Inc
OTC:BNNNF
|
JP |
|
Tetra Bio Pharma Inc
TSX:TBP
|
CA |
|
Reko International Group Inc
XTSX:REKO
|
CA |
|
A
|
Anagenics Ltd
ASX:AN1
|
AU |
|
Swoop Holdings Ltd
ASX:SWP
|
AU |
|
C
|
Companhia Energetica do Rio Grande do Norte Cosern
BOVESPA:CSRN6
|
BR |
|
J
|
J L Morison (India) Ltd
BSE:506522
|
IN |
|
S
|
Sino Grandness Food Industry Group Ltd
SGX:T4B
|
CN |
|
A
|
AVIC Joy Holdings Hk Ltd
HKEX:260
|
HK |
Balance Sheet
Balance Sheet Decomposition
Arecor Therapeutics PLC
Arecor Therapeutics PLC
Balance Sheet Decomposition is not available for
Arecor Therapeutics PLC
Arecor Therapeutics PLC
Balance Sheet
Arecor Therapeutics PLC
Arecor Therapeutics PLC
Currency: GBP
| May-2017 | May-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
1
|
1
|
3
|
3
|
18
|
5
|
5
|
3
|
|
| Cash |
1
|
1
|
3
|
3
|
18
|
5
|
5
|
3
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
8
|
2
|
0
|
|
| Total Receivables |
1
|
1
|
1
|
1
|
2
|
3
|
3
|
4
|
|
| Accounts Receivables |
1
|
0
|
0
|
0
|
1
|
1
|
3
|
3
|
|
| Other Receivables |
0
|
0
|
0
|
1
|
1
|
2
|
1
|
1
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
|
| Total Current Assets |
2
|
2
|
4
|
4
|
21
|
17
|
11
|
8
|
|
| PP&E Net |
1
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
|
| PP&E Gross |
1
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
|
| Accumulated Depreciation |
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
2
|
2
|
0
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
|
| Total Assets |
3
N/A
|
2
-19%
|
4
+108%
|
4
-1%
|
21
+388%
|
22
+4%
|
15
-29%
|
9
-43%
|
|
| Liabilities | |||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
1
|
2
|
7
|
1
|
|
| Accrued Liabilities |
0
|
0
|
0
|
1
|
1
|
1
|
2
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Total Current Liabilities |
1
|
1
|
1
|
1
|
2
|
4
|
5
|
3
|
|
| Long-Term Debt |
0
|
1
|
0
|
2
|
0
|
0
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
1
N/A
|
1
+13%
|
1
-21%
|
4
+220%
|
2
-32%
|
4
+82%
|
6
+36%
|
3
-42%
|
|
| Equity | |||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
4
|
5
|
8
|
11
|
17
|
23
|
31
|
41
|
|
| Additional Paid In Capital |
6
|
6
|
12
|
12
|
23
|
29
|
29
|
35
|
|
| Other Equity |
0
|
0
|
0
|
0
|
11
|
11
|
11
|
12
|
|
| Total Equity |
1
N/A
|
1
-50%
|
3
+379%
|
1
-76%
|
19
+2 297%
|
17
-6%
|
10
-45%
|
5
-44%
|
|
| Total Liabilities & Equity |
3
N/A
|
2
-19%
|
4
+108%
|
4
-1%
|
21
+388%
|
22
+4%
|
15
-29%
|
9
-43%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
28
|
28
|
28
|
28
|
28
|
31
|
31
|
38
|
|
Switch to:
Switch to:
See Also
Discover More
